Karo Bio to present clinical phase III development plan for eprotirome as a novel pharmaceutical for the treatment of HeFH
STOCKHOLM, August 11, 2010. The Swedish biotech company Karo Bio AB (publ) (Reuters: KARO.ST) today announced that the development plan for the upcoming phase III studies of eprotirome as a novel pharmaceutical for the treatment of high-risk patients with heterozygous familial hypercholesterolemia (HeFH) will be presented on Thursday August 26, 2010. In connection to the presentation, Professors Steven Nissen and John Kastelein will share their insights on the regulatory landscape for dyslipidemia drugs and clinical testing of pharmaceuticals for HeFH.Karo Bio recently announced a strategy